|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Parameters of a severe disease course in ulcerative colitis显示文摘AIM:To detect high risk patients with a progressive disease course of ulcerative colitis(UC) requiring immunosuppressive therapy(IT).METHODS:A retrospective,multicenter analysis of 262 UC patients from eight German tertiary inflammatory bowel disease centres was performed.Patients were divided into two groups depending on the patients need to initiate immunosuppressive therapy in the disease course.A comparison between the two groups was made with regard to demographics,clinical and laboratory parameters obtained within three months after UC diagnosis and the response to first medical therapy.Using this data,a prognostic model was established to predict the individual patients probability of requiring an immunosuppressive therapy.RESULTS:In 104(39.7%) out of 262 patients,UC therapy required an immunosuppressive treatment.Patients in this group were significantly younger at time of diagnosis(HR = 0.981 ± 0.014 per year,P = 0.009),and required significantly more often a hospitalisation(HR = 2.5 ± 1.0,P < 0.001) and a systemic corticosteroid therapy at disease onset(HR = 2.4 ± 0.8,P < 0.001),respectively.Response to steroid treatment was significantly different between the two groups of patients(HR = 5.2 ± 3.9 to 50.8 ± 35.6 compared to no steroids,P = 0.016 to P < 0.001).Furthermore,in the IT group an extended disease(HR = 3.5 ± 2.4 to 6.1 ± 4.0 compared to proctitis,P = 0.007 to P = 0.001),anemia(HR = 2.2 ± 0.8,P < 0.001),thrombocytosis(HR = 1.9 ± 1.8,P = 0.009),elevated C-reactive protein(CRP)(HR = 2.1 ± 0.9,P < 0.001),and extraintestinal manifestations in the course of disease(HR = 2.6 ± 1.1,P = 0.004) were observed.Six simple clinical items were used to establish a prognostic model to predict the individual risk requiring an IT.This probability ranges from less than 2% up to 100% after 5 years.Using this,the necessity of an immunosuppressive therapy can be predicted in 60% of patients.Our model can determine the need for an immunosuppressive drug therapy or if a 'watch and wait' approach is reasonable already early in the treatment course of UC.CONCLUSION:Using six simple clinical parameters,we can estimate the patients individual risk of developing a progressive disease course. | Andreas Stallmach Luisa Nickel Thomas Lehmann Bernd Bokemeyer Martin Bürger Dietrich Hüppe Wolfgang Kruis Susanna Nikolaus Jan C Preiss Andreas Sturm Niels Teich Carsten Schmidt | 2014 | World Journal of Gastroenterology2014，20，35： | 2 |
| 2 | Fluorouracil,leucovorin,and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer显示文摘 | Bokemeyer C Bondarenko I Makhson A | | Journal of Clinical Oncology0，，： | 2 |
| 3 | KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab:The OPUS experience显示文摘 | Bokemeyer C Bondarenko I Hartmann JT | 2008 | J Clin Oncol2008，26，5： | 1 |
| 4 | Fluorouraci,leucovorin,and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer显示文摘 | Bokemeyer C Bondarenko L | 2008 | J Clin Oncol2008，27，6： | 1 |
| 5 | Cetuximab plus 5- FU/FA/oxaliplutin (FOLFOX-4) versus FOLFOX-4 in the first-line treaanent of metastatic colorectal cancer (mCRC) : OPUS, a randomized phase II study显示文摘 | Bokemeyer C Bondarenko I Makhson A | 2007 | J Clin Oncol2007，，： | 1 |
| 6 | Fluorouracil, leu- covorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer 显示文摘 | Bokemeyer C Bondarenko I Makhson A | 2009 | J Clin Oncol2009，27，5： | 1 |
| 7 | KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab显示文摘 | Bokemeyer C Bondarenko I Hartmann JT | 2008 | J Clin Oncol2008，26，： | 1 |
| 8 | Fluoro- uracil, leucovorin, and oxaliplatin with and without ce- tuximab in the first-line treatment of metastatic colorectal cancer显示文摘 | Bokemeyer C Bondarenko I Makhson A | 2009 | J Clin Oncol2009，27，5： | 1 |
| 9 | Long-term g- ondai toxicity after therapy for Hodgkins and non-Hodgkin, s iymphoma 显示文摘 | BOKEMEYER C SCHM H J VANRHEE J | 1994 | Ann Hemato1994，68，3： | 1 |
| 10 | Extragonadal germ cell tumors:Relationt to testicular neoplasia and management options显示文摘 | Bokemeyer C Hartmann JT | 2003 | APMIS2003，111，1： | 1 |
| 11 | KRAS status and efficacy of first- line treatments of patients with metastatic colorectal cancer (mCRC) with FOL- FOX with or without cetuximab: the OPUS experience显示文摘 | Bokemeyer C Bondarenko I Hartmann J T De Braud F G Volovat C Nippgen J | 2008 | J Clin Oncol2008，2620，： | 1 |
| 12 | Predictive Impact of 2-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography for Residual Postchemotherapy Masses in Patients With Bulky Seminoma显示文摘 | de SANTIS M BOKEMEYER C BECHERER A | 2001 | J Clin Oncol2001，17，28： | 1 |
| 13 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS studv显示文摘 | BOKEMEYER C BONDARENKO I HARTMANN J T | 2011 | Ann Oneal2011，22，7： | 1 |
| 14 | Efficacy according to biomarker status of cetuximab puls FOLFOX-4 as first-line treatment for metastatic colorectal cancer:the OPUS study显示文摘 | Bokemeyer C Bondarenko I Hartmann JT | 2011 | Ann Oncol2011，22，7： | 1 |
| 15 | Extragonadal germ cell tumors: relation to testicular neoplasia and management options显示文摘 | Bokemeyer C Hartmanmn J T Fossa S D | 2003 | APMIS2003，111，1： | 1 |
| 16 | EORTC guidelines for the use of erythmpoietic proteins in anenlic patients with cancer:2006 update显示文摘 | Bokemeyer C Aapro MS Courdi A | 2007 | Eur J Cancer2007，43，： | 1 |
| 17 | K-RAS status and ei~cacy of first-line treat-ment of patients with metastatic colorectal can- cer (Mcrc) with FOLFOX with or without cetux- imab: the OPUS experience显示文摘 | BOKEMEYER C BONDARENKO I HARTMANN J T | 2008 | J Clin Oncol2008，26，15： | 1 |
| 18 | Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features显示文摘 | Maehtens S Serth J Bokemeyer C | 2001 | Int J Cancer2001，95，5： | 1 |
| 19 | Cetuximab plus 5-FU/ FA/ oxaliplatin ( FOLFOX-4 ) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC) : OPUS, a randomized phase Ⅱ study 显示文摘 | BOKEMEYER C BONDARENKO I MAKHSON A | 2007 | J Clin Oncol2007，25，18： | 1 |
| 20 | I)reclinical ac-tivity of a new platinum analogue, lohaplatin, in cisplatin-sensi-tive and resistant human testicular, ovarian and gastric carcinomacell lines显示文摘 | Harstrick A Bokemeyer C Scihamofkse M | 1993 | Cancer Chemother Pharm1993，33，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员